Development and Validation of a Prognostic Molecular Phenotype and Clinical Characterization in Grade III Diffuse Gliomas Treatment with Radio-Chemotherapy
Weiguo Gu,1,2,* Jiaming Tang,2,* Penghui Liu,1 Jinyu Gan,1 Jianfei Lai,1 Jinbiao Xu,2 Jianxiong Deng,2 Chaoxing Liu,1 Yuhua Wang,2 Guohua Zhang,3 Feng Yu,1,2 Chao Shi,2,3 Ke Fang,2 Feng Qiu2,3 1Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang U...
Saved in:
| Main Authors: | Gu W, Tang J, Liu P, Gan J, Lai J, Xu J, Deng J, Liu C, Wang Y, Zhang G, Yu F, Shi C, Fang K, Qiu F |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-01-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/development-and-validation-of-a-prognostic-molecular-phenotype-and-cli-peer-reviewed-fulltext-article-TCRM |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights
by: Hengzeng Li, et al.
Published: (2025-06-01) -
Evolution of radiotherapy and chemotherapy practice in malignant gliomas
by: Anusheel Munshi, et al.
Published: (2013-05-01) -
Pediatric Non–Brain Stem High-Grade Glioma: A Single-Center Experience
by: Ehsan Alimohammadi, et al.
Published: (2020-06-01) -
Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors
by: Supriya Mallick, et al.
Published: (2015-01-01) -
Phase I clinical trial of a novel procaspase-3 activator SM-1 with temozolomide in recurrent high-grade gliomas
by: Mengqian Huang, et al.
Published: (2025-03-01)